JP6858784B2 - サブトラクティブイムノアッセイ方法およびその方法を実施するためのラテラルフローイムノクロマトグラフィーアッセイストリップ - Google Patents
サブトラクティブイムノアッセイ方法およびその方法を実施するためのラテラルフローイムノクロマトグラフィーアッセイストリップ Download PDFInfo
- Publication number
- JP6858784B2 JP6858784B2 JP2018541502A JP2018541502A JP6858784B2 JP 6858784 B2 JP6858784 B2 JP 6858784B2 JP 2018541502 A JP2018541502 A JP 2018541502A JP 2018541502 A JP2018541502 A JP 2018541502A JP 6858784 B2 JP6858784 B2 JP 6858784B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- analyte
- detection
- sample
- capture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000003556 assay Methods 0.000 title claims description 47
- 238000000034 method Methods 0.000 title claims description 34
- 238000003018 immunoassay Methods 0.000 title claims description 30
- 238000003317 immunochromatography Methods 0.000 title claims description 15
- 238000001514 detection method Methods 0.000 claims description 167
- 239000012491 analyte Substances 0.000 claims description 97
- 239000000523 sample Substances 0.000 claims description 96
- 238000012360 testing method Methods 0.000 claims description 79
- 241000191967 Staphylococcus aureus Species 0.000 claims description 50
- 230000021615 conjugation Effects 0.000 claims description 49
- 101710096749 Penicillin-binding protein 2A Proteins 0.000 claims description 45
- 101710202686 Penicillin-sensitive transpeptidase Proteins 0.000 claims description 45
- 239000011324 bead Substances 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 239000000020 Nitrocellulose Substances 0.000 claims description 23
- 229920001220 nitrocellulos Polymers 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 230000005291 magnetic effect Effects 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 10
- 229960003085 meticillin Drugs 0.000 claims description 10
- 230000001268 conjugating effect Effects 0.000 claims description 7
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 230000007613 environmental effect Effects 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 101000735344 Lymantria dispar Pheromone-binding protein 2 Proteins 0.000 claims 2
- 229930182555 Penicillin Natural products 0.000 claims 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 2
- 229940049954 penicillin Drugs 0.000 claims 2
- 101710205263 Peptidoglycan D,D-transpeptidase MrdA Proteins 0.000 description 37
- 101710116427 Probable peptidoglycan D,D-transpeptidase PenA Proteins 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 20
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 10
- 230000003115 biocidal effect Effects 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000005298 paramagnetic effect Effects 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 102000011632 Caseins Human genes 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108090000279 Peptidyltransferases Proteins 0.000 description 3
- 238000002820 assay format Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000000834 fixative Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 150000003952 β-lactams Chemical class 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000012960 Immunoglobulin kappa-Chains Human genes 0.000 description 2
- 108010090227 Immunoglobulin kappa-Chains Proteins 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 108010068385 carbapenemase Proteins 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 1
- 101100026178 Caenorhabditis elegans egl-3 gene Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 101710128530 Fibrinogen-binding protein Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- BGPVFRJUHWVFKM-UHFFFAOYSA-N N1=C2C=CC=CC2=[N+]([O-])C1(CC1)CCC21N=C1C=CC=CC1=[N+]2[O-] Chemical compound N1=C2C=CC=CC2=[N+]([O-])C1(CC1)CCC21N=C1C=CC=CC1=[N+]2[O-] BGPVFRJUHWVFKM-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 230000006295 S-nitrosylation Effects 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 102000025748 fibrinogen binding proteins Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007973 glycine-HCl buffer Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 229940074409 trehalose dihydrate Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH15792015 | 2015-10-29 | ||
| CH1579/15 | 2015-10-29 | ||
| PCT/EP2016/075566 WO2017072078A1 (en) | 2015-10-29 | 2016-10-24 | Subtractive immunoassay method and lateral flow immunochromatography assay strip for performing the method |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533021A JP2018533021A (ja) | 2018-11-08 |
| JP2018533021A5 JP2018533021A5 (enExample) | 2019-12-05 |
| JP6858784B2 true JP6858784B2 (ja) | 2021-04-14 |
Family
ID=55649971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541502A Active JP6858784B2 (ja) | 2015-10-29 | 2016-10-24 | サブトラクティブイムノアッセイ方法およびその方法を実施するためのラテラルフローイムノクロマトグラフィーアッセイストリップ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10914738B2 (enExample) |
| EP (1) | EP3368901A1 (enExample) |
| JP (1) | JP6858784B2 (enExample) |
| WO (1) | WO2017072078A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4022310A4 (en) * | 2019-08-29 | 2022-10-26 | Aronowitz, Mireya, C. | QUANTITATIVE DETECTION OF ANALYTES IN LATERAL FLOW IMMUNOCHEMISTRY |
| FR3110703B1 (fr) | 2020-05-20 | 2024-11-29 | Vetophage | Dispositif de detection d’une bacterie d’interet |
| CN114487404B (zh) * | 2021-12-28 | 2023-06-23 | 中国农业大学 | 用于检测细菌内碳青霉烯酶的免疫层析试纸条及检测方法 |
| FR3159174A1 (fr) | 2024-02-12 | 2025-08-15 | Vetophage | Proteines pour la detection de streptococcus uberis et dispositifs de detection |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7659107B2 (en) * | 2003-09-23 | 2010-02-09 | Epinex Diagnostics, Inc. | Rapid test for glycated albumin |
| US20100221747A1 (en) | 2005-12-14 | 2010-09-02 | Denka Seiken Co., Ltd. | Immunochromatography detection of multidrug-resistant staphylococcus and diagnostic kit |
| WO2007074812A1 (ja) * | 2005-12-26 | 2007-07-05 | Bl Co., Ltd. | Ａ型インフルエンザウイルスｈ５亜型の検出法 |
| US9372191B2 (en) * | 2006-12-08 | 2016-06-21 | Alere Switzerland Gmbh | Methods and devices for detecting methicillin resistant Staphylococcus aureus |
| EP1933146B1 (en) * | 2006-12-11 | 2011-08-24 | AraGen Biotechnology Co. Ltd. | Rapid immunochromatographic detection by amplification of the colloidal gold signal |
| US7875433B2 (en) * | 2007-02-26 | 2011-01-25 | Response Biomedical Corporation | Comparative multiple analyte assay |
| US20120077684A1 (en) * | 2007-12-26 | 2012-03-29 | O'hara Shawn Mark | Methods and Compositions Including Diagnostic Kits For The Detection In Samples Of Methicillin-Resistant Staphylococcus Aureus |
| KR100943302B1 (ko) * | 2009-03-11 | 2010-02-23 | 다이노나(주) | 메치실린-내성 황색포도상구균 특이적 항체, 상기 항체를 이용하는 메치실린 내성 황색포도상구균 탐지방법, 및 탐지키트 |
| WO2011081075A1 (ja) * | 2009-12-28 | 2011-07-07 | キッコーマン株式会社 | 黄色ブドウ球菌抗原の抽出方法、黄色ブドウ球菌抗原の抽出用試薬および黄色ブドウ球菌の判定方法 |
| BR112016022829B1 (pt) * | 2014-04-02 | 2022-03-03 | Chembio Diagnostic Systems, Inc | Dispositivo de teste para determinar a presença de um primeiro ligante em uma amostra líquida, e método para testar uma amostra quanto à presença de um primeiro ligante |
| JP5767362B1 (ja) * | 2014-04-25 | 2015-08-19 | 田中貴金属工業株式会社 | 免疫クロマト分析装置、免疫クロマト分析方法及び免疫クロマト分析キット |
| JP5775197B1 (ja) * | 2014-04-30 | 2015-09-09 | 田中貴金属工業株式会社 | 免疫クロマト分析キット及び免疫クロマト分析方法 |
-
2016
- 2016-10-24 WO PCT/EP2016/075566 patent/WO2017072078A1/en not_active Ceased
- 2016-10-24 US US15/770,249 patent/US10914738B2/en active Active
- 2016-10-24 JP JP2018541502A patent/JP6858784B2/ja active Active
- 2016-10-24 EP EP16784934.8A patent/EP3368901A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180321238A1 (en) | 2018-11-08 |
| JP2018533021A (ja) | 2018-11-08 |
| US10914738B2 (en) | 2021-02-09 |
| EP3368901A1 (en) | 2018-09-05 |
| WO2017072078A1 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9910036B2 (en) | Method and device for combined detection of viral and bacterial infections | |
| EP2335072B1 (en) | Method and device for combined detection of viral and bacterial infections | |
| RU2617400C2 (ru) | Способ детекции специфического вещества в молоке | |
| US20050272106A1 (en) | Methods and kits for detection of multiple pathogens | |
| US20050260695A1 (en) | Methods, compositions, devices, and kits for detecting mastitis | |
| US8679812B2 (en) | Method for extracting Staphylococcus aureus antigen, reagent for extracting Staphylococcus aureus antigen, and method for assessing Staphylococcus aureus | |
| ES2843954T3 (es) | Método y dispositivo para detectar enterobacterias productoras de carbapenemasa | |
| US20140322724A1 (en) | Homogeneous competitive lateral flow assay | |
| JP6858784B2 (ja) | サブトラクティブイムノアッセイ方法およびその方法を実施するためのラテラルフローイムノクロマトグラフィーアッセイストリップ | |
| US20170336404A1 (en) | Rapid immunoassays | |
| UA125669C2 (uk) | Спосіб і обладнання для диференціювання вірусних інфекцій і бактеріальних інфекцій | |
| KR20160120675A (ko) | 래피드 정량 진단 키트 | |
| JPWO2004048975A1 (ja) | 黄色ブドウ球菌の検査方法 | |
| Kong et al. | A quantum dot fluorescent microsphere based immunochromatographic strip for detection of brucellosis | |
| EP1580558A1 (en) | Method of inspecting staphylococcus aureus | |
| WO2024036134A2 (en) | Defensin proteins for infection assessment | |
| HK40028169B (zh) | 用於鉴别病毒性感染与细菌性感染的方法和设备 | |
| JP2009288065A (ja) | Ｓｈｉｇａｔｏｘｉｎ２ｅ及びＳｈｉｇａｔｏｘｉｎ２ｅに対する抗体の検出方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191024 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191024 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200827 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200929 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201224 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210226 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210324 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6858784 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |